Why EyePoint stock is drawing attention now

EyePoint (EYPT) has moved back into focus after a solid 1 day gain of about 3.8%, extending its month and past 3 months returns and contrasting with a negative year to date performance.

That recent 3.8% one-day share price gain at around $13.85 comes after a 90-day share price return of 8.2%, but a year-to-date decline of 20.8%. Meanwhile, the 1-year total shareholder return of about 102% and 3-year total shareholder return of roughly 114% point to strong longer-term outcomes, suggesting momentum has been choppy rather than moving in a single direction.

If EyePoint has caught your attention, it can be useful to see what else is moving in related areas, including companies in healthcare and AI via the 33 healthcare AI stocks

With EyePoint trading around $13.85, a value score of 2, an analyst price target near $37.17 and an intrinsic value estimate suggesting a large discount, investors may ask whether there is a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 63% Undervalued

EyePoint's most followed narrative pegs fair value at about $37.17 per share, compared with the last close of $13.85. This frames a wide gap that hinges on how its retinal pipeline plays out.

Analysts are assuming EyePoint's revenue will grow by 102.6% annually over the next 3 years. If EyePoint's profit margin were to converge on the industry average, you could expect earnings to reach $49.2 million (and earnings per share of $0.48) by about May 2029, up from $232.0 million loss today.

Want to see what is behind that sharp swing from heavy losses to positive earnings in the models? The narrative leans on aggressive revenue expansion, improving margins and a premium future earnings multiple that is more often associated with higher growth sectors. Curious which specific assumptions have the biggest impact on that $37.17 fair value and how sensitive they are to setbacks or slower uptake?

Result: Fair Value of $37.17 (UNDERVALUED)

However, this hinges on DURAVYU delivering as planned, since heavy reliance on a single lead asset and periods of very low revenue could quickly test that bullish setup.

Another angle on EyePoint's valuation

The SWS DCF model points to a fair value of about $77.52 per share, compared with the current $13.85 price. This difference suggests very large upside and supports the idea that the stock is undervalued. With such a wide gap, which perspective do you think reflects risk more realistically: the market or the model?

Next Steps

The mix of strong past returns and sizeable valuation gaps makes this story both exciting and uncertain. It is worth checking the underlying data, stress testing the assumptions for yourself and then weighing up the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you risk missing stocks that better match your goals. Use the tools available and keep stacking the odds in your favor.

• Spot underpriced opportunities before the crowd by scanning 48 high quality undervalued stocks to find stocks that pair solid fundamentals with attractive valuations.
• Prioritize resilience and sleep easier at night by reviewing 70 resilient stocks with low risk scores to focus on stocks that score well on stability and financial strength.
• Hunt for off-the-radar potential by checking screener containing 25 high quality undiscovered gems that may not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.